RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs December 8, 2015
Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689 September 29, 2015
Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia September 2, 2015
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia August 24, 2015
